Elizabeth J. Kelly, PhD

AstraZeneca

Disclosure(s): AstraZeneca: Employee, Stocks/Bonds

Poster(s):

• 1110 - AZD7442 (Tixagevimab/Cilgavimab) Demonstrates Potent In Vitro Activity Against SARS-CoV-2 Spike Variants Identified in Circulation and in Prophylaxis Clinical Studies
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 1160 - Treatment-Emergent Viral Variants in the Phase 3 TACKLE Trial Investigating Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for the Treatment of Mild to Moderate COVID-19 in Adults
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 1953 - Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCoV-19) vaccination
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET